Is TRXDW or RYLD a better dividend investment in 2026?

TRXDW currently yields 1333.33% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: TRXDW offers higher current income.

What is the dividend yield difference between TRXDW and RYLD?

TRXDW has a forward dividend yield of 1333.33% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 1321.19 percentage points.

Home › Compare › TRXDW vs RYLD

TRXDW vs RYLD: Dividend Comparison 2026

TRXDW yields 1333.33% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 TRXDW wins by $241528700.56M in total portfolio value

INVESTMENT

TIME HORIZON10 years

TRXDW

● Live price

1333.33%

Share price

$0.15

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$241528700.61M

Annual income

$210,475,860,072,406.56

Full TRXDW calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — TRXDW vs RYLD

📍 TRXDW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	TRXDW	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, TRXDW + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

TRXDW pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRXDW

Annual income on $10K today (after 15% tax)

$113,333.33/yr

After 10yr DRIP, annual income (after tax)

$178,904,481,061,545.56/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, TRXDW beats the other by $178,904,481,059,346.30/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRXDW + RYLD for your $10,000?

TRXDW: 50%RYLD: 50%

100% RYLD50/50100% TRXDW

Portfolio after 10yr

$120764350.33M

Annual income

$105,237,930,037,496.95/yr

Blended yield

87.14%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on TRXDW right now

TRXDW

Analyst Ratings

Buy

Hold

Consensus: Hold

Altman Z

-42.6

Piotroski

3/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRXDW buys

RYLD buys

No recent congressional trades found for TRXDW or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricTRXDWRYLD

Forward yield	1333.33% ✓	12.14%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$241528700.61M ✓	$44.5K
Annual income after 10y	$210,475,860,072,406.56 ✓	$2,587.35
Total dividends collected	$239239876.27M ✓	$18.8K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: TRXDW vs RYLD ($10,000, DRIP)

Year	TRXDW Portfolio	TRXDW Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$144,033	$133,333.33	$11,914	$1,213.65	+$132.1K → TRXDW
2	$1,948,924	$1,794,807.89	$14,099	$1,351.30	+$1.93M → TRXDW
3	$24,782,219	$22,696,870.86	$16,580	$1,494.55	+$24.77M → TRXDW
4	$296,245,945	$269,728,970.81	$19,384	$1,642.61	+$296.23M → TRXDW
5	$3,330,378,004	$3,013,394,842.54	$22,535	$1,794.70	+$3330.36M → TRXDW
6	$35,223,684,321	$31,660,179,856.69	$26,063	$1,950.00	+$35223.66M → TRXDW
7	$350,636,384,108	$312,947,041,885.16	$29,995	$2,107.69	+$350636.35M → TRXDW
8	$3,286,630,500,315	$2,911,449,569,318.85	$34,361	$2,266.99	+$3286630.47M → TRXDW
9	$29,021,346,295,663	$25,504,651,660,325.88	$39,194	$2,427.12	+$29021346.26M → TRXDW
10	$241,528,700,608,766	$210,475,860,072,406.56	$44,525	$2,587.35	+$241528700.56M → TRXDW

TRXDW vs RYLD: Complete Analysis 2026

TRXDW — Stock

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Full TRXDW Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this TRXDW vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRXDW vs SCHD TRXDW vs JEPI TRXDW vs O TRXDW vs KO TRXDW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.